Recent research on the epidemiology and preventive strategies of neonatal group B Streptococcus infection in the latest decade
GUO Meng-Yang, GAO Wei, YUAN Lin, YAO Kai-Hu
National Center for Children's Health/Beijing Children's Hospital, Capital Medical University/Laboratory of Microbiology, Beijing Pediatric Research Institute/Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China (, Email: com.cn)
摘要 孕妇筛查结合产时抗生素预防是目前预防新生儿B族链球菌(group B Streptococcus,GBS)感染的主要策略,推广使用这一策略有效降低了新生儿GBS早发型疾病的发病率,但GBS感染的疾病负担仍很严重。产时抗生素预防策略存在引起抗生素耐药性、不能有效预防GBS晚发型疾病等局限,研发和评估其他预防策略至关重要,同时还需要密切关注如何评估孕妇青霉素过敏,以及母亲GBS筛查阴性的新生儿GBS感染的预防等问题。近年来,GBS疫苗及其免疫学相关研究取得了一些进展,应用特异性疫苗有望进一步减少新生儿GBS感染。
Abstract:Currently, the main strategy for preventing neonatal group B Streptococcus (GBS) infection is prenatal screening combined with intrapartum antibiotic prophylaxis, which has effectively reduced the incidence of neonatal GBS early-onset disease. However, the burden of GBS infection is still significant. The intrapartum antibiotic prophylaxis strategy has limitations such as inducing antibiotic resistance and inability to effectively prevent GBS late-onset disease. It is crucial to develop and evaluate other prevention strategies, while paying close attention to assessing penicillin allergy in pregnant women and how to prevent GBS infection in neonates with negative maternal GBS screening. In recent years, there has been some progress in GBS vaccines and related immunological research, and the use of specific vaccines is expected to significantly reduce GBS infection in neonates.
GUO Meng-Yang,GAO Wei,YUAN Lin et al. Recent research on the epidemiology and preventive strategies of neonatal group B Streptococcus infection in the latest decade[J]. CJCP, 2023, 25(5): 534-540.
Anon. Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion, number 797[J]. Obstet Gynecol, 2020, 135(2): e51-e72. PMID: 31977795. DOI: 10.1097/AOG.0000000000003668.
Russell NJ, Seale AC, O'Sullivan C, et al. Risk of early-onset neonatal group B streptococcal disease with maternal colonization worldwide: systematic review and meta-analyses[J]. Clin Infect Dis, 2017, 65(suppl_2): S152-S159. PMID: 29117325. PMCID: PMC5850448. DOI: 10.1093/cid/cix655.
3 Public Health England. Group B streptococcal infections: guidance, data and analysis[EB/OL]. (2020-06-26)[2022-11-07]. https://www.gov.uk/guidance/group-b-streptococcal-infections.
4 Centers for Disease Control and Prevention. Group B strep home[EB/OL]. (2022-10-18)[2022-11-05]. https://www.cdc.gov/groupbstrep/clinicians/index.html.
6 World Health Organization. Urgent need for vaccine to prevent deadly group B Streptococcus[EB/OL]. (2021-11-02)[2022-11-04]. https://www.who.int/news/item/02-11-2021-urgent-need-for-vaccine-to-prevent-deadly-group-b-streptococcus.
8 GOV.UK. Laboratory surveillance of pyogenic and non-pyogenic streptococcal bacteraemia in England: 2020 update[EB/OL]. (2021-11-23)[2022-07-28]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036011/hpr1921_strptcccl-BSI_2020.pdf.
Nanduri SA, Petit S, Smelser C, et al. Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance[J]. JAMA Pediatr, 2019, 173(3): 224-233. PMID: 30640366. PMCID: PMC6439883. DOI: 10.1001/jamapediatrics.2018.4826.
Cho CY, Tang YH, Chen YH, et al. Group B streptococcal infection in neonates and colonization in pregnant women: an epidemiological retrospective analysis[J]. J Microbiol Immunol Infect, 2019, 52(2): 265-272. PMID: 28882582. DOI: 10.1016/j.jmii.2017.08.004.
Zhu Y, Huang J, Lin XZ, et al. Group B Streptococcus colonization in late pregnancy and invasive infection in neonates in China: a population-based 3-year study[J]. Neonatology, 2019, 115(4): 301-309. PMID: 30808831. DOI: 10.1159/000494133.
Huang J, Lin XZ, Zhu Y, et al. Epidemiology of group B streptococcal infection in pregnant women and diseased infants in mainland China[J]. Pediatr Neonatol, 2019, 60(5): 487-495. PMID: 31445795. DOI: 10.1016/j.pedneo.2019.07.001.
Ding Y, Wang Y, Hsia Y, et al. Systematic review and meta-analyses of incidence for group B Streptococcus disease in infants and antimicrobial resistance, China[J]. Emerg Infect Dis, 2020, 26(11): 2651-2659. PMID: 33079042. PMCID: PMC7588546. DOI: 10.3201/eid2611.181414.
Miselli F, Creti R, Lugli L, et al. Group B Streptococcus late-onset neonatal disease: an update in management and prevention[J]. Pediatr Infect Dis J, 2022, 41(6): e263-e266. PMID: 35446809. DOI: 10.1097/INF.0000000000003517.
Le Doare K, O'Driscoll M, Turner K, et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review[J]. Clin Infect Dis, 2017, 65(suppl_2): S143-S151. PMID: 29117324. PMCID: PMC5850619. DOI: 10.1093/cid/cix654.
Hughes RG, Brocklehurst P, Steer PJ, et al. Prevention of early-onset neonatal group B streptococcal disease: green-top guideline No. 36[J]. BJOG, 2017, 124(12): e280-e305. PMID: 28901693. DOI: 10.1111/1471-0528.14821.
19 Queensland Government . Queensland clinical guideline: early onset group B streptococcal disease[EB/OL]. (2022-08-08)[2022-11-04]. https://www.health.qld.gov.au/__data/assets/pdf_file/0026/626732/g-gbs.pdf.
Park C, Nichols M, Schrag SJ. Two cases of invasive vancomycin-resistant group B Streptococcus infection[J]. N Engl J Med, 2014, 370(9): 885-886. PMID: 24571775. DOI: 10.1056/NEJMc1308504.
Metcalf BJ, Chochua S, Gertz RE, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA[J]. Clin Microbiol Infect, 2017, 23(8): 574.e7-574.e14. PMID: 28257899. DOI: 10.1016/j.cmi.2017.02.021.
Huang J, Li S, Li L, et al. Alarming regional differences in prevalence and antimicrobial susceptibility of group B streptococci in pregnant women: a systematic review and meta-analysis[J]. J Glob Antimicrob Resist, 2016, 7: 169-177. PMID: 27837713. DOI: 10.1016/j.jgar.2016.08.010.
27 European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints - breakpoints and guidance[EB/OL]. (2022-01-01)[2022-11-10]. https://www.eucast.org/clinical_breakpoints.
Davanzo R, De Cunto A, Travan L, et al. To feed or not to feed? Case presentation and best practice guidance for human milk feeding and group B Streptococcus in developed countries[J]. J Hum Lact, 2013, 29(4): 452-457. PMID: 23507961. DOI: 10.1177/0890334413480427.
Ching NS, Buttery JP, Lai E, et al. Breastfeeding and risk of late-onset group B streptococcal disease[J]. Pediatrics, 2021, 148(3): e2020049561. PMID: 34385351. DOI: 10.1542/peds.2020-049561.
Collin SM, Lamb P, Jauneikaite E, et al. Hospital clusters of invasive Group B streptococcal disease: a systematic review[J]. J Infect, 2019, 79(6): 521-527. PMID: 31733233. DOI: 10.1016/j.jinf.2019.11.008.
Absalon J, Segall N, Block SL, et al. Safety and immunogenicity of a novel hexavalent group B Streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial[J]. Lancet Infect Dis, 2021, 21(2): 263-274. PMID: 32891191. PMCID: PMC9760110. DOI: 10.1016/S1473-3099(20)30478-3.
Fischer P, Pawlowski A, Cao D, et al. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women[J]. Vaccine, 2021, 39(32): 4489-4499. PMID: 34215454. DOI: 10.1016/j.vaccine.2021.06.046.
36 World Health Organization. Defeating meningitis by 2030: a global road map[EB/OL]. (2021-06-24)[2023-04-19]. https://www.who.int/publications/i/item/9789240025516.
Puopolo KM, Lynfield R, Cummings JJ.American Academy of Pediatrics, Committee on Fetus and Newborn, Committee on Infectious Diseases. Management of Infants at Risk for Group B Streptococcal Disease[J]. Pediatrics, 2019, 144(4): e20192350. PMID: 31570651. DOI: 10.1542/peds.2019-2350.